Form 4: ALX Oncology Holdings Inc. Executive Alan B. Sandler Reports Stock Option Grant

Chief Medical Officer Alan B. Sandler reports the acquisition of stock options in ALX Oncology Holdings Inc.

Summary

• On April 11, 2025, Alan B. Sandler, Chief Medical Officer of ALX Oncology Holdings Inc., acquired employee stock options for 125,000 shares.
• The exercise price of these options is $0.49 per share.
• The options vest on April 11, 2026, and expire on April 11, 2035.
• Following the transaction, Sandler directly owns 125,000 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects a standard executive compensation practice. The grant of options aligns management's interests with shareholders.

Positives

• The grant of stock options to the Chief Medical Officer aligns his interests with those of the shareholders, incentivizing him to improve the company's performance.

Industry Context

Stock option grants are a common practice in the biotechnology industry to attract and retain key executives and align their interests with those of the shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Comparable companies such as Amgen, Gilead, and Regeneron also utilize stock options as part of their executive compensation plans.
• The vesting schedule and exercise price are typical for such grants.

Stakeholder Impact

• The stock option grant could potentially dilute existing shareholders if the options are exercised.
• The grant incentivizes the Chief Medical Officer to work towards increasing shareholder value.

Key Dates

Keywords

ALX Oncology Holdings Inc., ALXO, Form 4, Stock Options, Insider Trading, Alan B. Sandler, Chief Medical Officer, Equity, Securities